On February 9, President Claudia Sheinbaum announced a pivotal agreement between the Mexican Health Department, Birmex (the Biologicals and Reagents Laboratories of Mexico), and the pharmaceutical companies Liomont and Moderna. This partnership aims to facilitate the production of messenger RNA vaccines within the country, marking a significant step in Mexico's capacity to develop its vaccine supply. Sheinbaum emphasized the importance of this agreement in promoting research and development of new vaccines domestically.

In her social media announcement, Sheinbaum stated that this collaboration with Moderna—one of the leading global companies in mRNA vaccine development—signifies a transformative moment for Mexico's public health landscape. The agreement is expected to enhance the country's self-sufficiency in vaccine production, particularly in the current context of the Covid-19 pandemic, as well as for addressing dengue and cancer in the future. She noted the proactive stance Mexico is taking towards its healthcare challenges through this agreement.

The implications of this agreement are substantial, as it not only showcases Mexico's commitment to improving its healthcare infrastructure but also positions the country as a player in the global pharmaceutical landscape. By fostering local production capabilities, Mexico may reduce dependency on foreign vaccines, thereby enhancing public health security for its citizens. This move aligns with broader efforts to strengthen health systems and ensure availability of essential vaccines against pressing health issues affecting the population.